Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Synairgen (SNG)

Price 6.60p on 18-04-2024 at 16:30:04
Change 0.15p 2.33%
Buy 7.18p
Sell 6.02p
Buy / Sell SNG Shares
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 7,748.00 at 6.2984p
Day's Volume: 247,694
Last Close: 6.60p
Open: 6.45p
ISIN: GB00B0381Z20
Day's Range 0.00p - 0.00p
52wk Range: 4.20p - 14.00p
Market Capitalisation: £13m
VWAP: 6.42209p
Shares in Issue: 201m

Sector: Medicine and Biotech

Listed In: FTSE AIM All-Share,

Recent Trades History Synairgen (SNG)
Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 7,748 6.2984p Ordinary
 14:46:03 - 18-Apr-24
Sell* 1,630 6.2984p Ordinary
 14:41:00 - 18-Apr-24
Sell* 26,500 6.30p Ordinary
 13:57:34 - 18-Apr-24
Buy* 70,000 6.6928p Ordinary
 12:39:16 - 18-Apr-24
Sell* 3,359 6.2984p Ordinary
 12:08:42 - 18-Apr-24
Sell* 26,000 6.2984p Ordinary
 10:33:52 - 18-Apr-24
Sell* 780 6.2984p Ordinary
 10:08:28 - 18-Apr-24
Sell* 205 6.0548p Ordinary
 10:03:19 - 18-Apr-24
Buy* 156 6.716p Ordinary
 10:02:24 - 18-Apr-24
Buy* 147 6.716p Ordinary
 10:01:53 - 18-Apr-24

Share Price History for Synairgen
Time period:
to
Date Open High Low Close Volume

Share News for Synairgen

IN BRIEF: Synairgen names Phytome's Joseph Colliver as CFO

11th Oct 2023 11:19

Synairgen PLC - Southampton, England-based drug discovery and biotechnology firm developing SNG001 antiviral treatment for lung infections - Appoints Joseph Colliver as chief financial officer with effect from November 6. Current CFO John Ward will step down from his role on November 3. Colliver has previously held CFO and senior commercial roles at Sativa Group Inc, and within the Kantar division of WPP PLC. He is currently CFO at Phytome Life Sciences Ltd, a pharmaceutical manufacturing firm focused on plant-based medicines. Read More

Synairgen promotes Marcin Mankowski to chief medical officer

3rd Oct 2023 09:59

(Alliance News) - Synairgen PLC on Tuesday promoted Marcin Mankowski to chief medical officer, effective immediately. Read More

IN BRIEF: Synairgen narrows interim loss on reduced R&D spending

21st Sep 2023 13:48

Synairgen PLC - Southampton, England-based drug discovery and biotechnology firm developing SNG001 antiviral treatment for lung infections - Pretax loss narrows to GBP5.2 million in six months that ended June 30 from GBP14.0 million a year before. Has no revenue either year, but research and development spending is reduced to GBP3.5 million from GBP11.1 million, as phase 3 Sprinter trial of SNG001 is mostly completed in 2022. Since the start of the second half, receives GBP2.4 million R&D tax credit, which adds to GBP14.6 million cash balance on June 30. Read More

UK shareholder meetings calendar - next 7 days

22nd Jun 2023 15:44

Read More

EARNINGS SUMMARY: Synairgen loss narrows; aims to develop SNG001

27th Apr 2023 14:44

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

FTSE 100 Latest
Value7,877.05
Change29.06

Login to your account

Forgot Password?

Not Registered